Nutrição mineral de Andropogon gayanus Kunth var. bisquomulatus (Hochst) Hack: IV. produção de matéria seca, concentração de nutrientes e coeficiente de digestibilidade

De uma área adubada e plantada, situada em uma terra roxa estruturada, amostras de Andropogon gayanus bisquamulatus foram coletadas em intervalos de 20 dias após a germinação, até aos 140 dias de idade e secas à 80°C. No material seco foi determinado o coeficiente de digestibilidade aparente in vivo empregando-se a técnica do "saco de nylon". Na época de produção máxima de matéria seca, aos 80 dias, foi determinada a concentração de macro e micronutrientes. Observou-se que o coeficiente de digestibilidade da matéria seca diminuiu com o aumento da idade das folhas. Aos 80 dias, época de maxima produção de matéria seca. O coeficiente de digestibilidade para as folhas foi 71,21% e para caules 66,47%. Aos 80 dias de idade, as folhas e caules apresentavam as seguintes concentrações: N% 1,36 a 0,79; P% 0,12 a 0,11; K% 1,79 a 2,41; Ca% 0,27 a 20,7; Mg% 0,16 a 0,16; S%0,07 a 0,06; B ppm 11,75 a 11,0; Cu ppm 4,75 a 3,75; Fe ppm 236,75 a 341,75; Mn ppm 74,50 a 94,00 e Zn ppm 22,25 a 21,00.

Determinação da digestibilidade de nutrientes através da técnica do "saco de nylon" mais pepsina

Procurou-se verificar se a digestão de alimento em saco de "nylon", acrescida por tratamento com pepsina, seria equivalente à digestão obtida pelo método direto clássico, o de coleta total de fezes, já determinado anteriormente com ovinos. Seguiu-se um delineamento experimental em blocos ao acaso, com 6 repetições e 4 tratamentos, ou seja, tratamento A: ração contendo 100% de feno de capim de Rhodes; B: 85% de feno de Rhodes mais 15% de farelo de côco; C: 70% de feno de Rhodes mais 30% de farelo de côco; e D: 100% de farelo de côco. O animal fistulado utilizado para teste foi um bovino adulto, macho, de raça holandesa; o tempo de permanência do saco de "nylon" no rume foi de 72 horas; e a dieta consistiu em feno de Rhodes à vontade mais 2kg de farelo de coco por dia. Os resultados foram analisados através de análise da variância e curvas de regressão, e a comparação entre métodos de digestibilidade pelo teste de Tukey. Houve influência da associação de alimentos sobre a digestibilidade da fibra bruta (FB) e dos extrativos não nitrogenados (ENN), mas não sobre as demais frações - matéria seca (MS), extrato etéreo (EE) e proteína bruta (PB). A digestibilidade da fibra diminuiu com a inclusão e o acúmulo do nível de farelo na dieta. Não houve equivalência consistente entre os métodos testados de digestiblidade, variando ou não conforme o nutriente e o tratamento considerado. De modo geral, a inclusão de aproximadamente 15% de farelo de côco (tratamento B) favoreceu o melhor aproveitamento da dieta.

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Nylon wool column: a tool for obtaining monokine-rich eluates in the absence of serum

Diverse conditions for stimulating human mononuclear cells to release thymocyte costimulatory factors were tested for their contribution to the generation of supernatants high titers of these monokines. Activity titers increased with LPS concentration, reaching a plateau between 1 and 10 microng/ml. Indomethacin did not modify the monokine, but the assay for thymocyte costimulatory activity was substantially affected by inhibitory substances produced by the monocytes in the absence of indomethacin. The use of nylon wool columns to trap the cells was shown to be effective in raising cellular densities without decreasing activity titers. As result, the yield per cell could be maintained even in the absence of serum, an important step toward the goal of purifiying bioactive from crude broths.

Subjective Memory Deficits in People with and without Dementia: Findings from the 10/66 Dementia Research Group Pilot Studies in Low- and Middle-Income Countries

OBJECTIVES To compare subjective memory deficit (SMD) in older adults with and without dementia or depression across multiple centers in low- and middle-income countries (LAMICs). DESIGN Secondary analysis of data from 23 case control studies. SETTING Twenty-three centers in India, Southeast Asia (including China), Latin America and the Caribbean, Nigeria, and Russia. PARTICIPANTS Two thousand six hundred ninety-two community-dwelling people aged 60 and older in one of three groups: people with dementia, people with depression, and controls free of dementia and depression. MEASUREMENTS SMD was derived from the Geriatric Mental State examination. RESULTS Median SMD frequency was lowest in participants without dementia (26.2%) and higher in those with depression (50.0%) and dementia (66.7%). Frequency of SMD varied between centers. Depression and dementia were consistently associated with SMD. Older age and hypochondriasis were associated with SMD only in subjects without dementia. In those with dementia, SMD was associated with better cognitive function, whereas the reverse was the case in controls. CONCLUSION Associations with SMD may differ between subjects with and without dementia living in LAMICs.

Archives parlementaires de 1787 à 1860 ; 52-61, 63-82. Convention nationale. Série 1 / Tome 66 / impr. par ordre du Sénat et de la Chambre des députés ; fondé par MM. Mavidal et E. Laurent ; continué́ par M. L. Lataste,... M. Louis Claveau,... M. Constant Pionnier,... [et al.]

Collection : Les archives de la Révolution française ; 3.1

Informe sobre estudios ornitológicos realizados en el laboratorio de la Puntilla (Pisco) en setiembre de 1965/66

Da a conocer algunas observaciones ornitológicas realizadas por espacio de dos años, en el Astillero de la Puntilla (Pisco). Presenta estudios ecológicos sobre las aves marinas, principalmente las guaneras peruanas.

The Recirculator, Vol. 66, No. 1, March 2010.

News for swimming pool and spa operators, mangers, and inspectors.

The Recirculator, Vol. 66, No. 2, October 2010.

News for swimming pool and spa operators, mangers, and inspectors.

The Recirculator, Vol. 66, No. 3, December 2010.

News for swimming pool and spa operators, mangers, and inspectors.